YCH2823 is a potent, selective USP7 inhibitor with IC50 of 49.6 nM, ITC Kd of 117 nM.

XL-9872-106C (XL-106C) is a potent, selective inhibitor of the deubiquitinase (DUB) JOSD1/USP30/UCHL1 with IC50 of 134/390/166 nM, respectively.

USP7-797 is a novel potent selective inhibitor of USP7 with IC50 of 0.44 nM.

TG2-179-1 is a potent, selective and covalently inhibitor of deubiquitinase (DUB) BRCA1-associated protein-1 (BAP1), covalently binds to the active site of BAP1 (Cys91), exhibits potent cytotoxic activity against colon cancer cells.

SB1-F-70 is a potent, selective inhibitor of the deubiquitinase (DUB) JOSD1/USP30/UCHL1 with IC50 of 324/400/400 nM, respectively.

OTUDin3 (OTUD3 inhibitor) is a specific, small molecule inhibitor of deubiquitylase OTUD3, binds to OTUD3 (KD=0.32 uM) and inhibits the deubiquitinating activity of OTUD3 by interfering with Ub binding to OTUD3.

NCI677397 is a specific small molecule inhibitor of USP24, inhibits chemotherapy-induced drug resistance in vitro and in vivo.

MTX115325 is a potent, selective, brain-penetrant USP30 inhibitor with IC50 of 12 nM in biochemical fluorescence polarization assays.

MS102 is a small molecule, orally available USP2 inhibitor with IC50 of 5.46 uM, induces transient degradation of ACE2 protein and inhibits ACE2-dependent coronavirus infection.

LN5P45 is a selective, covalent, irreversible inhibitor of ubiquitin thioesterase OTUB2 with IC50 of 2.3 uM, strongly induces monoubiquitination of OTUB2 on Lys31.

IU2-6 is a small molecule USP14 inhibitor, shows 74% inhibition at 8 uM.

IU1-206 is a IU1 derivative with more potent activity against USP14, 10-fold more potent than IU1 and is comparable to the IU1-47.

IMP-2373 is a highly targeted cyanopyrrolidine (CNPy) probe for pan-DUB to monitor DUB activity in physiologically relevant live cells.

I-138 (I 138) is a potent, specific small molecule USP1-UAF1 inhibitor with IC50 of 4.1 nM, binds to USP1-UAF1 at an allosteric pocket synergistically with ubiquitin.

HY041004 is the first small molecule inhibitor of deubiquitinase Josephin Domain-containing protein 2 (JOSD2) with IC50 of 0.26 uM for JOSD2 catalytic activity inhibition.

GK13S is a highly potent, specific and covalent inhibitor of deubiquitinase UCHL1 with IC50 of 87 nM, displays exquisite specificity for UCHL1 over the other UCH family members (IC50>10 uM).

FT385 (FT3967385) is a potent, selective USP30 inhibitor with biochemical IC50 of 1.5 nM.

FT206 (FT-206, FT3951206, CRT0511973) is a potent, selectivel inhibitor of USP28 with a remarkable USP28/25 selectivity.

DC-U4106 is a potent, selective small molecule inhibitor of Ubiquitin-specific protease 8 (USP8) with binding KD value of 4.7 uM, DC-U4106 is selective over USP2 and USP7.

CAS-12290-201 is a potent and selective inhibitor of deubiquitinating enzyme (DUB) VCPIP1 with IC50 of 70 nM, covalently and specificly targets the catalytic cysteine of VCPIP1 with little to no activity toward other cellular DUBs.

C673-0105 is a selective, small molecule inhibitor of USP10, inhibits USP10 comparably to HBX19818 (IC50=10 uM), with no inhibition against USP7 (IC50>100 uM.

C598-0556 is a selective, small molecule inhibitor of USP10, inhibits USP10 comparably to HBX19818 (IC50=10 uM), with no inhibition against USP7 (IC50>100 uM).

BML-260 (BML260) is a potent inhibitor of dual-specific phosphatase JSP-1 (JNK Stimulatory Phosphatase-1, DUSP22) and stimulator of uncoupling protein 1 (UCP-1) expression in adipocytes.

BK50118-C is a potent small molecule inhibitor of ubiquitin-specific protease-13 (USP13) with IC50 of 0.42 nM.

BAY-728 (NAY728) is a less potent enantiomer and negative control compound of BAY-805.

iBAP-II (BAP1 inhibitor II) is a next-generation, specific small molecule inhibitor of BAP1 histone H2A deubiquitinase activity with IC50 of <0.1 ug/mL.iBAP-II displays higher affinity for BAP1 than the closest UCH family member, UCHL5, and other deubiquitinases, such as USP5, USP7, USP8, TNFAIP3-catalytic domain, USP2-catalytic domain, Otubain-1, and Ataxin3.Inhibition of BAP1 via iBAP-II reduces ASXL3 protein stability in small cell lung cancer cells, without significant changes to ASXL1 and ASXL2 protein levels.iBAP-II suppresses ASCL1 expression in NCI-H1963 cells, along with the mRNA levels involving a handful of known ASCL1 transcriptional targeted genes, such as GRP, DMPK, RNF183, SCN3A, MYCL, and CACNA1A.iBAP-II exhibited more potent cell viability inhibition activity on four different BAP1-WT SCLC cell lines than iBAP.iBAP-II (50 mg/kg/d) significantly delayed the disease progression in SCLC xenograft model.

USP10 inhibitor Wu-5 (Wu-5) is a novel small molecule USP10 inhibitor inducing the degradation of FLT3-mutated protein, directly interacts and inactivates USP10, the deubiquitinase for FLT3-ITD in vitro (IC50=8.3 uM) and in FLT3-ITD-positive AML cells.Wu-5 selectively inhibited the viability of FLT3 inhibitor-sensitive (MV4-11, Molm13) and -resistant (MV4-11R) FLT3-ITD-positive AML cells with IC50 of 3.794, 5.056, and 8.386 uM, respectively.Wu-5 (1-10 μM) dose-dependently induced apoptosis of MV4-11, Molm13, and MV4-11R cells through the proteasome-mediated degradation of FLT3-ITD.Combined treatment of Wu-5 and crenolanib produced synergistic cell death in FLT3-ITD-positive cells via the reduction of both FLT3 and AMPKα proteins.

FT-671 is a novel potent, specific, non-covalent USP7 inhibitor with Kd of 65 nM (USP7 catalytic domain).

IMP-1710 (IMP1710) is a potent, selective, covalent UCHL1 inhibitor with IC50 of 38 nM.IMP-1710 demonstrated exquisite selectivity in a cross-screening against 20 DUBs.IMP-1710 can profile activity of endogenous UCHL1 with excellent selectivity in cell types including endothelial cells (EA.hy926) and adenocarcinoma human alveolar basal epithelial cells (A549).IMP-1710 demonstrated >50% fibroblast–myofibroblast transition (FMT) inhibition (IC50=740 nM) in idiopathic pulmonary fibrosis (IPF), as well as αSMA inhibition.IMP-1710 is a powerful and selective probe to explore UCHL1 activity with potential application to substrate identification, mode of action studies, and cellular target profiling.

FT709 is a potent and selective USP9X inhibitor, an IC50 of 82 nM. USP9X has been linked with centrosome function, chromosome alignment during mitosis, EGF receptor degradation, chemo-sensitization, and circadian rhythms.